Pharmaceutical solution formulations for pressurised metered dose inhalers
US-10525006-B2 · Jan 7, 2020 · US
Pharmaceutical solution formulations for pressurized metered dose inhalers
US11213485B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11213485-B2 |
| Application number | US-201916689611-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 20, 2019 |
| Priority date | Apr 21, 2006 |
| Publication date | Jan 4, 2022 |
| Grant date | Jan 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of severe or very severe broncho-pulmonary disease, which comprises administering to a subject in need thereof an effective amount of a pressurized solution formulation from a metered dose inhaler, which comprises two or more active drug substances in a predetermined ratio dissolved in an HFA propellant, consisting of HFA 134 a and a co-solvent, wherein, on actuation of said inhaler, substantially all of the liquid particles emitted contain said two or more active drug substances in a ratio which is substantially the same as said predetermined ratio of said two or more active drug substances and said two or more active drug substances are delivered with substantially the same particle size distribution, wherein said solution formulation comprises formoterol or a salt thereof and beclomethasone dipropionate, and wherein said formulation comprises ethanol as a cosolvent in an amount between 6% and 18% w/w, based on the total weight of said formulation. 2. The method according to claim 1 , wherein said formulation comprises formoterol fumarate. 3. The method according to claim 1 , wherein said broncho-pulmonary disease is severe persistent asthma. 4. The method according to claim 1 , wherein said broncho-pulmonary disease is severe chronic obstructive pulmonary disease. 5. The method according to claim 1 , wherein said broncho-pulmonary disease is very severe chronic obstructive pulmonary disease.
Assignees
Inventors
Classifications
Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title
- A61K9/08Primary
Solutions {(composition of solutions A61K47/00)} · CPC title
characterised by the propellant · CPC title
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone · CPC title
Antiasthmatics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11213485B2 cover?
- The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances ar…
- Who is the assignee on this patent?
- Chiesi Farm Spa
- What technology area does this patent fall under?
- Primary CPC classification A61K9/08. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).